Key findings
• The present study revealed a statistically significant increase in the maximum standardized uptake value and the tumor-to-background ratio of fluorine 18-labeled fibroblast activation protein inhibitor ( 18 F-FAPI-04) compared with fluorine-18 labeled-fluorodeoxyglucose ( 18 F-FDG) for stage IA lung adenocarcinoma (LUAD) (P<0.05).
What is known and what is new?
• 18 F-FDG positron emission tomography/computed tomography (PET/CT) is used for the staging and restaging of lung cancer, however, false-negative results may occur when evaluating nodules measuring below 1.0 cm (T1a), adenocarcinoma in situ , or minimally invasive adenocarcinoma.
• We compared the diagnostic value of 18 F-FDG PET/CT and 18 F-FAPI-04 PET/CT imaging in stage IA LUADs while assessing fibroblast activating protein (FAP) expression using immunohistochemistry in resected specimens.
What is the implication, and what should change now?
• 18 F-FAPI-04 PET/CT may be superior to 18 F-FDG PET/CT for detecting stage IA LUAD lesions. 18 F-FAPI-04 uptake in stage IA LUAD was significantly and positively correlated with ex vivo FAP expression.
Publication: Liang HX, Huang QW, He YM, Mai YQ, Chen ZL, Wang BP, Fang N, Hu JF, Li X, Zhang N, Liu ET, Li XC. Comparison of the diagnostic accuracy between 18 F-FAPI-04 PET/CT and 18 F-FDG PET/CT in the clinical stage IA of lung adenocarcinoma. J Thorac Dis 2025;17(2):661-675. doi: 10.21037/jtd-24-1658
Journal of Thoracic Disease
Observational study
People
Comparison of the diagnostic accuracy between 18F-FAPI-04 PET/CT and 18F-FDG PET/CT in the clinical stage IA of lung adenocarcinoma
27-Feb-2025
All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1658/coif). The authors have no conflicts of interest to declare.